Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients

Neuropsychopharmacology

Volumn 21, Issue 4, 1999, Pages 542-549

  Fukuzako, Hiroshi ^a   Fukuzako, Tsuyoshi ^a,b   Kodama, Satoshi ^a   Hashiguchi, Tomo ^a   Takigawa, Morikuni ^a   Fujimoto, Toshiro ^a,b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b South Japan Health Science Center   (Japan)

Author keywords

Haloperidol; Magnetic resonance spectroscopy; Phosphorus metabolites; Schizophrenia; Temporal lobe

Indexed keywords

HALOPERIDOL; MEMBRANE PHOSPHOLIPID; ORGANOPHOSPHATE; PHOSPHOLIPID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TEMPORAL LOBE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CELL MEMBRANE; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PHOSPHOLIPIDS; SCHIZOPHRENIA; TEMPORAL LOBE;

EID: 0032849894     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00050-0     Document Type: Article

References (43)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 3rd ed, revised:1987;American Psychiatric Association, Washington DC.
2. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Ponto L.L.B., Hichwa R.D. Hypofrontality in schizophrenia. Distributed dysfunctional circuits in neuroleptic-naïve patients Lancet. 349:1997;1730-1734.
3. Berman I., Merson A., Sison C., Allan E., Schaefer C., Loberboym M., Losonczy M.F. Regional cerebral blood flow changes associated with risperidone treatment in elderly schizophrenia patients. A pilot study Psychopharmacol Bull. 32:1996;95-100.
4. Bertolino A., Nawroz S., Matty V.S., Barnett A.S., Duyn J.H., Moonen C.T.W., Frank J.A., Tedeschi G., Weinberger D.R. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry. 153:1996;1554-1563.
5. Blüml S, Tan J, Adatia N, Karme A, Sproull T, Harris K, Ross BD (1998): Cerebral Glycerophosphorylcholine and Ethanolamine Concentrations Are Elevated in Young Schizophrenics (abstract). Proceedings of the 6th Annual Scientific Meeting (Sydney) SMR, p 736.
6. Deicken R.F., Merrin E.L., Floyd T.C., Weiner M.W. Correlation between left frontal phospholipids and Wisconsin Card Sorting Test performance in schizophrenia. Schizophr Res. 14:1995;177-181.
7. Deicken R.F., Zhou L., Schuff N., Fein G., Weiner M.W. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatry. 43:1998;483-488.
8. Egan M.F., Weinberger D.R. Neurobiology of schizophrenia. Curr Opin Neurobiol. 7:1997;701-707.
9. Farooqui A.A., Hirashima Y., Horrocks L.A. Brain phospholipases and their role in signal transduction. Bazan N.G., Murphy M.G., Tofano G. Neurobiology of Essential Fatty Acids. 1992;11-26 Plenum Press, New York.
10. Fukuzako H., Fukuzako T., Takeuchi K., Ohbo Y., Ueyama K., Takigawa M., Fujimoto T. Phosphorus magnetic resonance spectroscopy in schizophrenia. Correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms Prog Neuro-Psychopharmacol Biol Psychiatry. 20:1996;629-640.
11. 2 activity in schizophrenic patients. Reduction after neuroleptic therapy Biol Psychiatry. 22:1987;421-426.
12. 2 activity in schizophrenia. Schizophr Res. 16:1995;1-6.
13. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 30:1998;193-208.
14. Kaplan R.D., Szechtman H., Franco S., Szechtman B., Nahmias C., Garnett E.S., List S., Cleghorn J.M. Three clinical syndromes of schizophreniain untreated subjects. Relation to brain glucose activity measured by positron emission tomography Schizophr Res. 11:1993;47-54.
15. Keshavan M.S., Bagwell W.W., Haas G.L., Sweeney J.A., Schooler N.R., Pettegrew J.W. Changes in caudate volume with neuroleptic treatment. Lancet. 344:1994;1434.
16. Keshavan M.S., Pettegrew J.W., Panchalingam K. MRS in the study of psychoses. Psychopharmacological studies Nasrallah H.A., Pettegrew J.W. NMR Spectroscopy in Psychiatric Brain Disorders. 1995;131-146 American Psychiatric Press, Washington DC.
17. 31P NMR spectrum of human brain. The determination of the concentrations of phosphodiester components FEBS Lett. 272:1990;163-165.
18. Kitamura T., Yuzuriha T., Morita M., Itoh J., Suga R., Nakagawa Y. Oxford version of the BPRS. Development and validation of subscales Psychiatric Diag. 1:1990;101-107.
19. Klemm E., Danos P., Grünwald F., Kasper S., Möller H.-J., Biersack H.-J. Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression - a study with single photon emission computed tomography. Psychiatry Res Neuroimag. 68:1996;1-10.
20. Kolakowska T. Brief Psychiatric Rating Scale. Glossaries and Rating Instructions:1976;Oxford University, Oxford.
21. Lawrie S.M., Abukmeil S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies Br J Psychiatry. 172:1998;110-120.
22. Liddle P.F., Friston K.J., Frith C.D., Hirsch S.R., Jones T., Frackowiak R.S.J. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry. 160:1992;179-186.
23. Maier M. In vivo magnetic resonance spectroscopy. Applications in psychiatry Br J Psychiatry. 167:1995;299-306.
24. Matsuda H., Jibiki I., Kinuya S., Shuke N., Sumiya H., Tonami N., Hisada K. Tc-99m HMPAO SPECT analysis of neuroleptic effects on regional brain function. Clin Nucl Med. 16:1991;660-664.
25. McClure R.J., Keshavan M.S., Pettegrew J.W. Chemical and physiologic brain imaging in schizophrenia. Psychiatric Clin North Am. 21:1998;93-122.
26. 31P NMR spectra of the human brain in vivo. NMR Biomed. 7:1994;237-242.
27. Miller D.D., Rezai K., Alliger R., Andreasen N.C. The effect of antipsychotic medication on relative cerebral blood perfusion in schizophrenia. Assessment with technetium-99m hexamethyl-propyleneamine oxime single photon emission computed tomography Biol Psychiatry. 41:1997;550-559.
28. 31P NMR spectrum in vivo. Magn Reson Med. 12:1989;282-289.
29. Nilsson A., Risberg J., Johnason M., Gustafson L. Regional changes of cerebral blood flow during haloperidol therapy in patients with paranoid symptoms. Acta Neurol Scand. 64(suppl):1977;478-479.
30. Nordahl T.E., Kusubov N., Carter C., Salamat S., Cummings A.M., O'Shora-Celaya L., Eberling J., Robertson L., Huesman R.H., Jagust W., Budinger T.F. Temporal lobe metabolic differences in medication-free outpatients with schizophrenia via the PET-600. Neuropsychopharmacology. 15:1996;541-554.
31. Oldfield R.C. The assessment and analysis of handedness. The Edinburgh Inventory Neuropsychologia. 9:1971;97-113.
32. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., Allen M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy Arch Gen Psychiatry. 48:1991;563-568.
33. 1H decoupling (abstract). Proceedings of the 4th Annual Scientific Meeting (New York) SMR, p 998.
34. Puri B.K., Richardson A.J. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentanoic acid. Arch Gen Psychiatry. 55:1998;188-189.
35. 2 Arch Gen Psychiatry. 54:1997;487-494.
36. Sabri O., Erkwoh R., Schreckenberger M., Owega A., Sass H., Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet. 349:1997;1735-1739.
37. Schachter S.C., Ransil B.J., Geschwind N. Associations of handedness with hair color and learning disabilities. Neuropsychologia. 25:1987;269-276.
38. Shioiri T., Kato T., Inubushi T., Murashita J., Takahashi S. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Res Neuroimag. 55:1994;223-235.
39. Singh S.P., Shankar R. Effect of haloperidol on phospholipid biosynthesis in rat brain. Ind J Exp Biol. 34:1996;111-114.
40. Stanley JA, Panchalingam K, Miller G, McClure RJ, Pettegrew JW (1997): A new method to quantify the broad component under the phosphodiester resonance and its application to study first-episode never medicated schizophrenics (abstract). Proceedings of the 5th Annual Scientific Meeting (Vancouver) SMR, p 1408.
41. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett R.J., Malla A., Thompson R.T. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry. 52:1995;399-406.
42. Williamson P.C., Braner M., Leonard S., Thompson T., Drost D. 31P magnetic resonance spectroscopy studies in schizophrenia. Prostagland Leukot Essent Fatty Acids. 55:1996;115-118.
43. Zipursky R.B., Zhang-Wong J., Lambe E.K., Bean G., Beiser M. MRI correlates of treatment response in first episode psychosis. Schizophr Res. 30:1998;81-90.